

#20  
Amdt. Rec'd  
1/14/03

ATTENTION: BOX AFTER FINAL  
RESPONSE UNDER 37 C.F.R. § 1.116  
EXPEDITED PROCEDURE REQUESTED  
EXAMINING GROUP 1648



PATENT

Customer No. 22,852  
Attorney Docket No. 2356.0011-06

RECEIVED

JAN 13 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

ALIZON et al.

Application No.: 09/041,975

Filed: March 13, 1998

For: VARIANT OF LAV VIRUSES

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

AMENDMENT AFTER FINAL

In reply to the Final Office Action of July 16, 2002, and pursuant to 37 C.F.R. § 1.116, Applicants propose that this application be amended as follows:

IN THE CLAIMS:

Please add new claims 39-41 as follows:

D1 cont'd N/A  
39. (NEW) A purified HIV-1 variant virus,

wherein said HIV-1 variant virus differs at the amino acid sequence level from the group of viruses consisting of HIV-1<sub>IIIB</sub>, HIV-1<sub>BRU</sub>, and HIV-1<sub>ARV-2</sub> at least 9.8% in the entire Gag protein, 5.5% in the entire Pol protein, and 20.7% in the entire Env protein,

01/09/2003 OCHAU1 00000030 09041975

03 FEB 1207

\$4.00 0P  
\$4.00 0P